A phase 1 trial has reported positive safety findings of SON-1010 among patients with advanced leiomyosarcoma (LMS) or ...

Early clinical results suggest the firm's antibodies targeting the Vβ T-cell receptor could induce strong and durable responses in cancer patients.

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% ...

Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor ...

The management of breast cancer involves various therapeutic approaches. However, many current anticancer treatments indiscriminately damage both cancerous and healthy cells. In cancer treatment, ...

A groundbreaking study published in Research (2025, DOI: 10.34133/research.0545) has elucidated the molecular mechanisms by which protein phosphatase 2A (PP2A) regulates CD8+ T cell-mediated immune ...

Researchers have shed new light on how tissues in the body are repaired following the damage and premature death of tissue ...

PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative ...

A growing body of work suggests that cell metabolism — the chemical reactions that provide energy and building materials — ...

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

Researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a ...

Immunodeficient mouse holding human tumor cells and human immune cells demonstrates tumor metastasis in the lungs. Such tumor metastasis is prevented by short synthetic mRNA injections, as they ...